Literature DB >> 22213202

Flavokawain B, a kava chalcone, induces apoptosis in synovial sarcoma cell lines.

Toshinori Sakai1, Ramez N Eskander, Yi Guo, Kap Jung Kim, Jason Mefford, Justin Hopkins, Nitin N Bhatia, Xiaolin Zi, Bang H Hoang.   

Abstract

Synovial sarcomas (SS) are soft tissue sarcomas with poor prognosis, displaying a lack of response to conventional cytotoxic chemotherapy. Although SS cell lines have moderate chemosensitivity to isofamide and doxorubicin therapy, the clinical prognosis is still poor. In this article, we showed that flavokawain B (FKB), a novel chalcone from kava extract, potently inhibits the growth of SS cell lines SYO-I and HS-SY-II through induction of apoptosis. Treatment with FKB increased caspase 8, 9, and 3/7 activity compared to vehicle-treated controls, indicating that both extrinsic and intrinsic apoptotic pathways were activated. Furthermore, FKB treatment of both cell lines resulted in increased mRNA and protein expression of death receptor-5 and the mitochondrial pro-apoptotic proteins Bim and Puma, while down-regulating the expression of an inhibitor of apoptosis, survivin in a dose-dependent manner. Our results suggest the natural compound FKB has a pro-apoptotic effect on SS cell lines. FKB may be a new chemotherapeutic strategy for patients with SS and deserves further investigation as a potential agent in the treatment of this malignancy.
Copyright © 2011 Orthopaedic Research Society.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22213202      PMCID: PMC3685290          DOI: 10.1002/jor.22050

Source DB:  PubMed          Journal:  J Orthop Res        ISSN: 0736-0266            Impact factor:   3.494


  19 in total

Review 1.  The morphology of apoptosis.

Authors:  G Häcker
Journal:  Cell Tissue Res       Date:  2000-07       Impact factor: 5.249

2.  From the Centers for Disease Control and Prevention. Hepatic toxicity possibly associated with kava-containing products--United States, Germany, and Switzerland, 1999-2002.

Authors: 
Journal:  JAMA       Date:  2003-01-01       Impact factor: 56.272

3.  The correlation between cancer incidence and kava consumption.

Authors:  G G Steiner
Journal:  Hawaii Med J       Date:  2000-11

4.  Synovial sarcoma: a multivariate analysis of prognostic factors in 112 patients with primary localized tumors of the extremity.

Authors:  J J Lewis; C R Antonescu; D H Leung; D Blumberg; J H Healey; J M Woodruff; M F Brennan
Journal:  J Clin Oncol       Date:  2000-05       Impact factor: 44.544

5.  Molecular abnormalities of p53, MDM2, and H-ras in synovial sarcoma.

Authors:  Y Oda; A Sakamoto; T Satio; S Kawauchi; Y Iwamoto; M Tsuneyoshi
Journal:  Mod Pathol       Date:  2000-09       Impact factor: 7.842

6.  Flavokawain B inhibits growth of human squamous carcinoma cells: Involvement of apoptosis and cell cycle dysregulation in vitro and in vivo.

Authors:  Elong Lin; Wen-Hsin Lin; Sheng-Yang Wang; Chih-Sheng Chen; Jiuun-Wang Liao; Hsueh-Wei Chang; Ssu-Ching Chen; Kai-Yuan Lin; Lai Wang; Hsin-Ling Yang; You-Cheng Hseu
Journal:  J Nutr Biochem       Date:  2011-05-02       Impact factor: 6.048

Review 7.  TRAIL death receptors as tumor suppressors and drug targets.

Authors:  Niklas Finnberg; Wafik S El-Deiry
Journal:  Cell Cycle       Date:  2008-03-24       Impact factor: 4.534

8.  Hepatic toxicity possibly associated with kava-containing products--United States, Germany, and Switzerland, 1999-2002.

Authors: 
Journal:  MMWR Morb Mortal Wkly Rep       Date:  2002-11-29       Impact factor: 17.586

9.  Tara up-regulates E-cadherin transcription by binding to the Trio RhoGEF and inhibiting Rac signaling.

Authors:  Tomoki Yano; Yuji Yamazaki; Makoto Adachi; Katsuya Okawa; Philippe Fort; Masami Uji; Shoichiro Tsukita; Sachiko Tsukita
Journal:  J Cell Biol       Date:  2011-04-11       Impact factor: 10.539

10.  BAX activation is initiated at a novel interaction site.

Authors:  Evripidis Gavathiotis; Motoshi Suzuki; Marguerite L Davis; Kenneth Pitter; Gregory H Bird; Samuel G Katz; Ho-Chou Tu; Hyungjin Kim; Emily H-Y Cheng; Nico Tjandra; Loren D Walensky
Journal:  Nature       Date:  2008-10-23       Impact factor: 49.962

View more
  19 in total

1.  Kava chalcone, flavokawain A, inhibits urothelial tumorigenesis in the UPII-SV40T transgenic mouse model.

Authors:  Zhongbo Liu; Xia Xu; Xuesen Li; Shuman Liu; Anne R Simoneau; Feng He; Xue-Ru Wu; Xiaolin Zi
Journal:  Cancer Prev Res (Phila)       Date:  2013-10-11

2.  Silencing of survivin by YM155 induces apoptosis and growth arrest in hepatocellular carcinoma cells.

Authors:  Changhe Zhang; Xiaofei Cao; Yongxiang Gei; Yong Wang; Guiyuan Liu; Guochang Cheng; Qinghong Liu
Journal:  Oncol Lett       Date:  2015-07-02       Impact factor: 2.967

Review 3.  Molecular targeted approaches to cancer therapy and prevention using chalcones.

Authors:  Danielle D Jandial; Christopher A Blair; Saiyang Zhang; Lauren S Krill; Yan-Bing Zhang; Xiaolin Zi
Journal:  Curr Cancer Drug Targets       Date:  2014       Impact factor: 3.428

4.  In vivo antitumor and antimetastatic effects of flavokawain B in 4T1 breast cancer cell-challenged mice.

Authors:  Nadiah Abu; Nurul Elyani Mohamed; Swee Keong Yeap; Kian Lam Lim; M Nadeem Akhtar; Aimi Jamil Zulfadli; Beh Boon Kee; Mohd Puad Abdullah; Abdul Rahman Omar; Noorjahan Banu Alitheen
Journal:  Drug Des Devel Ther       Date:  2015-03-06       Impact factor: 4.162

Review 5.  The importance of being dead: cell death mechanisms assessment in anti-sarcoma therapy.

Authors:  Santiago Rello-Varona; David Herrero-Martín; Laura Lagares-Tena; Roser López-Alemany; Núria Mulet-Margalef; Juan Huertas-Martínez; Silvia Garcia-Monclús; Xavier García Del Muro; Cristina Muñoz-Pinedo; Oscar Martínez Tirado
Journal:  Front Oncol       Date:  2015-04-07       Impact factor: 6.244

6.  Aplysin sensitizes cancer cells to TRAIL by suppressing P38 MAPK/survivin pathway.

Authors:  Jia Liu; Leina Ma; Ning Wu; Ge Liu; Lanhong Zheng; Xiukun Lin
Journal:  Mar Drugs       Date:  2014-09-25       Impact factor: 5.118

7.  Dietary feeding of Flavokawain A, a Kava chalcone, exhibits a satisfactory safety profile and its association with enhancement of phase II enzymes in mice.

Authors:  Xuesen Li; Xia Xu; Tao Ji; Zhongbo Liu; Mai Gu; Bang H Hoang; Xiaolin Zi
Journal:  Toxicol Rep       Date:  2014

8.  Flavokawain B, a kava chalcone, inhibits growth of human osteosarcoma cells through G2/M cell cycle arrest and apoptosis.

Authors:  Tao Ji; Carol Lin; Lauren S Krill; Ramez Eskander; Yi Guo; Xiaolin Zi; Bang H Hoang
Journal:  Mol Cancer       Date:  2013-06-10       Impact factor: 27.401

9.  The flavokawains: uprising medicinal chalcones.

Authors:  Nadiah Abu; Wan Yong Ho; Swee Keong Yeap; M Nadeem Akhtar; Mohd Puad Abdullah; Abdul Rahman Omar; Noorjahan Banu Alitheen
Journal:  Cancer Cell Int       Date:  2013-10-22       Impact factor: 5.722

Review 10.  Anticancer principles from medicinal piper ( hú jiāo) plants.

Authors:  Yue-Hu Wang; Susan L Morris-Natschke; Jun Yang; Hong-Mei Niu; Chun-Lin Long; Kuo-Hsiung Lee
Journal:  J Tradit Complement Med       Date:  2014-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.